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in regard to public funding criteria. The following main types of restrictions were 
identiﬁ ed either because of the target public funding parameter affected or because of 
the reasoning: a) “because of lack of evidence”; b) “because it is the only effective 
treatment” (rule of rescue); c) “to improve efﬁ cacy”; d) “to improve efﬁ cacy-safety 
relation”; e) “to improve effectiveness”; f) “to improve cost-effectiveness”; and g) “to 
limit budget impact”. CONCLUSIONS: The limiting conditions should be perceived 
as tools to enable positive public funding decision when the current scope of ﬁ nancing 
is just behind the hypothetical threshold. Exploring and further analyzing methods 
and aspects concerning generating public funding restrictions is important for: 1) 
decision makers, so they be more aware of the consequences and impact of their 
decisions on the people/patients they serve, and could make more transparent deci-
sions; 2) HTA analysts, to focus their interest on the subsequent use of HTAs to help 
decision makers identify all potential options to rationally limit funding; 3) Market 
Access managers, so they used the identiﬁ ed mechanisms and methods to better foresee 
the public funding decisions concerning their drugs.
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ASSESSING PUBLIC ACCOUNTABILITY OF KOREAN DRUG 
REIMBURSEMENT DECISION PROCESS
Cho E, Kang M
Yonsei University, Seoul, South Korea
OBJECTIVES: Since economic evaluation has been enforced to be considered for new 
drug reimbursement decisions in 2007, the structure and constituents of decision body, 
“Drug Reimbursement Evaluation Committee”, as well as the pharmacoeconomics 
report guideline promulgated by Health Insurance Review Assessment have been 
modiﬁ ed in Korea. These changes reﬂ ect deﬁ ciency in systematic adoption of economic 
evaluation and discontent among stakeholders. Recently, the fair and reasonable 
process and criteria have been highly emphasized at every level of policy administra-
tion in developed countries with concerns of increasing public demands for sustainable 
public practices and political acceptance of the importance of public accountability. 
Now, imminent practical task is how to connect the conceptual framework and fea-
sible practice for publicly accountable drug reimbursement decisions. METHODS: 
Using theoretical structure of public accountability published in the European Gover-
nance Paper, we analyzed qualiﬁ cations of drug reimbursement policy as ‘account-
ability’ and appraised the public accountability. We also performed interviews with 
ten key stakeholders from democratic, constitutional and learning perspectives. And 
then, recent reimbursement decision papers on two new drugs were analyzed to 
examine concrete shape of the accountability forums. RESULTS: Following scope of 
improvement would be suggested: (1) Clear and reasonable standards for coverage 
decision; (2) relevance of the standards to population’s health needs and health equity 
impacts; (3) disclosure of data used for decision, procedure and results to public; and 
(4) the procurement of due process of challenging decisions. CONCLUSIONS: Given 
value pluralism in democratic liberalism, it is matter of course that formal or proce-
dural justice is given prominence. Conclusively, an explicit discussion for formal cri-
teria and procedure is the essential component of the ongoing policy process. 
Accountable drug policy administration is impossible without accountable policy 
process which is impossible without transparent criteria for all decision stages.
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BACKGROUND: In Western jurisdictions, coverage with evidence development (CED) 
is seen as a promising scheme for linking coverage decisions on innovative health tech-
nologies with the generation of additional evidence. Nonetheless, the implementation of 
such CED schemes is not guaranteed to be successful, with issues arising around both 
evidence generation and (dis)continued coverage of technologies. OBJECTIVES: This 
qualitative study aims to explore the practical experiences with CED schemes for tech-
nology coverage. METHODS: Semi-structured interviews were conducted with key 
stakeholders involved in the decision making process about reimbursement of health 
technologies in Australia, Belgium, Ontario (Canada), France, Germany, Galicia (Spain), 
Sweden, UK and USA. The questionnaire for the interview was developed on the basis 
of comprehensive literature review and expert opinion, addressing issues related to the 
aim of CED, initial assessment/appraisal, evidence development, re-assessment/re-
appraisal and coverage for technologies. RESULTS: CED schemes vary widely in the 
evidence generation, time frame, the regulation and funding of research, and the involve-
ment of stakeholders in the CED process. This variation is caused by the structure and 
ﬁ nancing of health services delivery, the aim of CED, and the type of health technology. 
The CED process is often non-transparent, particularly relating to the selection of 
technologies and the re-assessment/re-appraisal for coverage (dis)continuation. (Dis)
continued coverage of technologies is often primarily driven by the pressures from 
patients, health professional and health institutions to provide access to innovative 
technologies or public opinion. CONCLUSIONS: The successful implementation of 
CED schemes requires: a) a transparent (analytic) framework for the selection of health 
technologies and the generation of additional evidence; b) a clear legal authority to regu-
late evidence generation, time frame and research budget; c) a structural involvement of 
stakeholders in the process of CED; and d) a priori clear end points for the re-assessment/
re-appraisal and technology coverage. 
HEALTH CARE USE & POLICY STUDIES – Health Care Research & 
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BACKGROUND: The Dutch reimbursement procedure for expensive hospital drugs 
requires the submission of a baseline cost-effectiveness analysis together with a 
research plan for the period of temporary reimbursement in order to estimate the 
real-life cost-effectiveness after 4 years. In this situation, a Value-of-Information (VOI) 
analysis might identify the critical parameters that need to be studied in such outcome 
study. OBJECTIVES: To identify when a VOI analysis alongside sensitivity analyses 
is warranted, and when such VOI analysis will not impact the decision making process. 
METHODS: We used a hypothetical Markov model with three groups of parameters: 
costs, utilities and transition probabilities. We studied different conﬁ gurations of input 
parameters, forcing the outcomes into different directions on the CE-plane. For each 
input conﬁ guration we performed a multivariate sensitivity analysis (MSA) and a 
probabilistic sensitivity analysis (PSA). In the MSA, sensitivity was measured as per-
centage change from baseline INMB. Additionally, we analyzed the expected value of 
perfect information (EVPI) and the expected value of partial perfect information 
(EVPPI). Analyses were done for a range of threshold ICERs. RESULTS: For each 
situation it was possible to predict the shape (but not the absolute value) of the EVPI 
curve based on the PSA ﬁ ndings. When the PSA plot covered both northern quadrants, 
MSA and EVPPI came to the same ranking of the groups of parameters. When the 
outcomes were in the northeast quadrant the ranking differed: MSA indicated costs 
as most important parameters, for EVPPI this was utilities. When outcomes where in 
the southwest quadrant, costs were most important in MSA and EVPPI. For both 
other quadrants, MSA and EVPPI were close to zero for all groups. CONCLUSIONS: 
Whether MSA and EVPPI come to a different priority setting for future research 
depends both on the threshold ICER and on the location of results on the 
CE-plane.
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OBJECTIVES: To identify stakeholder perceptions of sponsored clinical trials in a 
publically funded New Zealand hospital, and then to identify the similarities and 
differences in perceptions across these stakeholder groups. The stakeholders are: 1) 
participants involved in clinical trials; 2) management and the multidisciplinary team; 
3) the larger South Auckland community; 4) government and decision makers; and 5) 
the pharmaceutical industry. METHODS: We use purposive sampling to select repre-
sentatives of the stakeholder groups, which provides 109 respondents. We gather data 
using focus groups, in-depth interviews, telephone interviews and surveys. RESULTS: 
Many of the respondents represent more than one stakeholder group. While there is 
consensus across the stakeholders on some costs and beneﬁ ts such as developing safe 
medicines and collecting useful data there are marked differences in perceptions in 
other areas, such as those indicated below. Most stakeholders perceive the risk of 
adverse reactions as the greatest cost to trial participants but the participants them-
selves do not regard this as signiﬁ cant. Pharmaceutical representatives, management 
and the multidisciplinary team feel that gaining access to new medicines motivates 
people to participate in a trial. Trial participants feel that the support is more impor-
tant to them than the medication. Most researchers and staff believe trial involvement 
increases their job satisfaction, motivation, knowledge and skills while a few have 
concerns that sponsor control leads to the loss of their ﬂ exibility and independence 
Generally there is a perception that New Zealand based clinical trials assist in the 
process of obtaining registration and subsidization of new drugs in New Zealand. 
However, this perception may be erroneous as location of trials is apparently not 
considered in the drug registration process. CONCLUSIONS: We ﬁ nd that most 
stakeholders are satisﬁ ed with the conduct of clinical trials in New Zealand and they 
believe the beneﬁ ts outweigh the costs.
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OBJECTIVES: Recent development of Health Technology Assessment worldwide 
increased requirement for real world data (e,g, risk management plans, drugs utiliza-
tion). Primary non-interventional research (NIR) involving physicians able to enrol 
patients is a means to generate such data. One key challenge of NIRs is the capacity 
to reﬂ ect real life conditions by providing unbiased estimations of physicians’ behav-
iours and patients outcomes in large representative samples. Participation of physi-
cians is often an issue when conducting NIRs. Lack of understanding of scientiﬁ c value 
of NIRs, compared to clinical trials, is often assumed to be the major reason for 
reluctance to participate. Our objective was to better understand perception of, moti-
vation to participate in and expectation from participation in NIRs by physicians. 
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METHODS: A survey was conducted in France on representative samples of 196 
psychiatrists, 221 cardiologists and 250 general practitioners. Demographic charac-
teristics were used to check representativeness. Perception of NIRs’ scientiﬁ c interest, 
motivation criteria and expectations were assed and analyzed using descriptive statis-
tics. RESULTS: >70% of physicians are convinced that NIRs are of scientiﬁ c interest 
and provide reliable information on drug utilization in real life conditions. However, 
10–15% are not convinced, 10–20% don’t have any opinion. Motivation relates to 
interest for scientiﬁ c objective and studied disease (>90%), scientiﬁ c rigour and cred-
ibility of partners (IRB review, scientiﬁ c committee, sponsor) (>70%). NIRs requested 
by Health Authorities are not incentive. Physicians appreciate contributing to improv-
ing knowledge about drugs (>80%). >70% consider NIRs a challenging opportunity 
to compare their behaviour to their peers’. All (>90%) are interested in receiving 
results. 49% and 89% think results should be available within 6 and 12 months 
respectively. CONCLUSIONS: NIRs are recognized as a rigorous scientiﬁ c tool by a 
majority of physicians. Motivation to participate is based on all scientiﬁ c components 
of NIR. Results are expected in short term timeframe.
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OBJECTIVES: The new act on developing of the Hungarian health care system—came 
into effect on the 1st of April 2007 cut the number of hospital beds signiﬁ cantly in 
Hungary and the National Institute of Psychiatry and Neurology (OPNI) was closed. 
The aim of our paper is to analyze the effect of the 2007 Hungarian health care reform 
on the number of psychiatric hospital beds. METHODS: Data were derived from the 
nationwide administrative data set of the National Health Insurance Fund Administra-
tion (OEP), the only health care ﬁ nancing agency in Hungary. The number of both 
acute and chronic care hospital beds was evaluated before and after 1st of April 2007. 
RESULTS: The 2007 act on developing of the Hungarian health care system cut the 
total number of acute care hospital beds by 15.631 (26 %) from 59.846 to 44.215 
(from 59,2 to 43,7 beds per 10000 inhabitants) and increased the total number of 
chronic care hospital beds by 7.069 (35 %) from 20.100 to 27.169. The number of 
acute psychiatric beds was reduced from 3.644 beds to 2.750 (−894 or −24,5% 
decrease). At the same time, the number of chronic care psychiatric beds was increased 
from 4.898 beds to 5.091 (193 or +3,9% increase). Altogether, 701 psychiatric beds 
were eliminated from the Hungarian health care system. CONCLUSIONS: Although 
the total number of chronic care hospital beds was increased by 35 % within the 
Hungarian health care reform in 2007, the Hungarian health care system lost 701 
psychiatric care hospital beds without any reasonable consideration or explanation.
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OBJECTIVES: The new act on developing of the Hungarian health care system—came 
into effect on the 1st of April 2007 cut the number of hospital beds signiﬁ cantly in 
Hungary and the National Institute of Psychiatry and Neurology (OPNI) was closed. 
The aim of our paper is to analyze the effect of 2007 Hungarian health care reform 
on the number of psychiatric care hospital beds at regional level. METHODS: Data 
were derived from the nationwide administrative data set of the National Health 
Insurance Fund Administration (OEP), the only health care ﬁ nancing agency in 
Hungary. We carefully review the formal legislation and informal background papers 
related to this issue. The number of hospital beds was evaluated before and after 1st 
of April 2007. RESULTS: We found signiﬁ cant regional differences in the number of 
acute care psychiatric beds according to counties in Hungary. The number of acute 
psychiatric hospital beds per 10,000 inhabitants was the highest in the following 
counties: Békés 4.56; Szabolcs-Sz-B 4.18; Komárom-E 3.67; Budapest 3.56. The 
number of acute psychiatric hospital beds per 10,000 inhabitants was the lowest in 
the following counties: Zala 1.69; Somogy 1.50; Heves 1.48; J-N-Szolnok 1.36; Vas 
1.13. CONCLUSIONS: Following the 2007 hospital bed reform in Hungary, there is 
a 4 times differences in the number of acute care psychiatric beds among the Hungar-
ian counties. We did not ﬁ nd any reasonable consideration or explanation behind that 
fact.
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OBJECTIVES: Given the increased use of interventions of knowledge translation to 
change clinical practice, it is necessary to evaluate their effectiveness and cost-effec-
tiveness. In this systematic review we synthesized scientiﬁ c evidence on the cost-
effectiveness of knowledge translation methods in health professionals. METHODS: 
We searched studies in MEDLINE and EconLit databases up to March 2010. Com-
plete economic evaluations based on clinical trials of knowledge translation in primary 
and specialized health care were selected, if published in English, Spanish, German or 
Italian. The primary outcome was the incremental cost-effectiveness ratio. Quality of 
the economic evaluations was assessed by the check-list by Drummond et al. The 
extracted information was presented in text and tables. RESULTS: Eighteen economic 
evaluations met the inclusion criteria. The knowledge translation interventions were 
aimed at different areas, like prescription, diagnostics, treatment, counselling and 
clinical practice guidelines. Thirteen studies were cost-effectiveness analyses, and ﬁ ve 
were cost-utility analyses. The effectiveness measures used in the cost-effectiveness 
studies are mainly intermediate results, while the cost-utility studies use mainly the 
QALYs (quality-adjusted life-years). The perspective mostly used was the one of health 
care system. Training/education is the intervention most frequently assessed followed 
by feedback, academic detailing, software support and distribution of educational 
materials; eight studies combined two or more methods. Most of the interventions are 
effective in knowledge translation, i.e. fulﬁ l the function for which they have been 
designed. CONCLUSIONS: Although the scientiﬁ c evidence suggests that the knowl-
edge translation interventions are effective, most of them are relatively costly, and 
therefore less cost-effective. Those interventions that require less resources or can be 
applied in different areas at low cost, should be developed and implemented.
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OBJECTIVES: Objective of this study is to discover whether OTC package designs 
differ in their ability to transfer drug safety related information to pharmacy custom-
ers. The research was intended to answer two questions: 1) how well (in terms of 
speed and accuracy) do customers comprehend the relevant medical information on 
packages? 2) do alternative package designs cause signiﬁ cantly different levels of 
comprehension?. METHODS: Face-to-face interviews with 452 customers of 17 
German pharmacies were conducted. In each of three sequential experiments (one 
OTC brand per experiment), each of the participants was shown two packages of the 
same brand (Paracetamol/Bisacodyl) and asked three drug-related questions per 
package. Multivariate linear regression analysis was used to identify the factors 
capable of explaining the accuracy of the answers (ﬁ rst outcome; quality) and the 
speed with which the answers were made (second outcome; time). The different abili-
ties of the three package designs to transfer information correctly and rapidly were 
compared by descriptive statistics. The signiﬁ cance of the differences was tested by 
Wilcoxon tests. RESULTS: Older people, those with physiological problems, people 
not in a good mood, and those with a poor doctor-patient relationship, or a lack of 
trust in medicines in general answered the questions with a signiﬁ cantly higher number 
of mistakes and/or needed signiﬁ cantly longer to do so. When compared to two other 
package designs, one of the tested designs proved itself to be superior in quality and 
time. CONCLUSIONS: 1) There exist signiﬁ cant differences between patient groups 
in their ability to comprehend medical information; speciﬁ c patients do not understand 
medical information on packages in a sufﬁ cient way. 2) The design of a medication 
package can measurably inﬂ uence the quality and speed of information transfer to 
pharmacy customers. An optimized package design is a source of added value from a 
drug safety point of view.
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BACKGROUND: Despite adequate literature on the effectiveness of behaviour change 
strategies for physicians, there is little information on whether these strategies are 
cost-effective. OBJECTIVES: To review the current literature on the cost-effectiveness 
of behaviour change policies for health care professionals. METHODS: A search of 
the MEDLINE database and of reference lists was performed up to May 2010. 
RESULTS: Twelve economic evaluations, assessing sixteen interventions in total, were 
identiﬁ ed. These were performed in either Europe or Australia. All but one evaluation 
had a control group, which received either no intervention (5) or a standard, less 
labour intensive intervention (7) (One evaluation had two phases and therefore two 
control groups). The type of control group had no association with whether the 
strategy was deemed cost-effective or not. Seven of the policies were deemed cost-
effective by the authors (remuneration, telemarketing, outreach, training sessions (3), 
distance learning), six were deemed not (outreach (4), training session, courier delivery 
of guidelines) and three reported increased beneﬁ ts with increased costs but did not 
conclude whether this was cost-effective (outreach (2), training session). Three studies 
actually reported decreased costs with the test intervention over control, two of which 
were due to decreased hospital referrals. Of those behaviour change policies not 
deemed cost-effective, 50% had minimal or no increase in effect and the other 50% 
had a very signiﬁ cant increase in costs. CONCLUSIONS: Not all strategies were found 
to be cost-effective, which highlights the necessity of this type of analysis before major 
behaviour change policies are implemented. Multiple studies found that there were 
increased beneﬁ ts with increased costs. With no deﬁ ned threshold as to what makes 
a behaviour change policy cost-effective, the discussion is open to debate as to whether 
these beneﬁ ts are worth the increased costs.
